Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has shared an announcement.
Hisamitsu Pharmaceutical Co., Inc. announced the acquisition of 1,765,400 of its own shares, costing approximately 7.1 billion yen, as part of a previously announced plan. This move is part of a broader strategy to repurchase up to 3 million shares by the end of 2025, which could impact the company’s market positioning and shareholder value.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceutical products. The company is known for its transdermal therapeutic products and has a significant presence in the Japanese market.
Average Trading Volume: 169,148
Technical Sentiment Signal: Sell
Current Market Cap: Yen299.4B
Learn more about 4530 stock on TipRanks’ Stock Analysis page.